Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects
NCT07059403Phase 1Active, not recruiting
- Sponsor
- Chimivac
- Start
- Aug 2025
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Chimigen Hepatitis B vaccine in Chronic Hepatitis B (CHB) (3 cohorts), sponsored by Chimivac. Primary endpoints: Incidence of adverse events at 48 weeks, Number of subjects with clinically significant abnormalities in vital signs at 48 weeks and 3 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
Chimigen Hepatitis B vaccine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07059403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059403.